TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02962219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative Exercise Programme (my-PEP)
Description: A pre-operative personalised exercise programme (my-PEP) consisting of: 1) actions to promote exercise, using behavioural change techniques (BCTs), 2) home inspiratory muscle training (IMT), 3) a home exercise programme (HEP) - which is also current standard care, 4) a 4 week hospital-supervised aerobic and muscle strengthening programme (Hos-PEP) .

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home Exercise Programme (HEP)
Description: Written advice on exercise at home
Study: NCT02440295

Intervention type: PROCEDURE
Intervention: Lower Extremity Amputation

Intervention type: DEVICE
Intervention: SPY Elite Imaging System
Description: The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.

Intervention type: DRUG
Intervention: Indocyaine Green
Description: Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
Study: NCT03043729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2, as 2h infusion on Day 1 (Arm A + Arm B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2, as 2h infusion on Day 1 (Arm A + Arm B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU 400 mg/m\^2 i.v. as bolus on Day 1 and 2400 mg/m\^2 as 46 h infusion q2w (Arm A + Arm B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 400 mg/m\^2 i.v. as bolus on Day 1 and 2400 mg/m\^2 as 46 h infusion q2w (Arm A + Arm B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (Arm B, Cycles 1 to 5)
Study: NCT02469532

Intervention type: DEVICE
Intervention: Balloon Angioplasty
Description: Device: Balloon Angioplasty Selection is driven by preference of the operator

Intervention type: DEVICE
Intervention: Atherectomy System
Description: Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
Study: NCT00862654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)
Description: Association: clobetasol propionate shampoo \& ketoconazole shampoo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)
Description: Association: clobetasol propionate shampoo \& ketoconazole shampoo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobetasol propionate shampoo (2/week)
Description: Monotherapy with clobetasol propionate shampoo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole shampoo (2/week)
Description: Monotherpay ketoconazole shampoo (2/week)
Study: NCT04179435

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral testing on cognitive computerized tasks
Description: Testing on cognitive computerized tasks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral testing on cognitive computerized tasks
Description: Testing on cognitive computerized tasks

Intervention type: OTHER
Group type: OTHER
Intervention: brain MRI
Description: Brain MRI scans

Intervention type: OTHER
Group type: OTHER
Intervention: brain MRI
Description: Brain MRI scans

Intervention type: OTHER
Group type: OTHER
Intervention: TMS
Description: Measure of the cortical inhibitory capacity using TMS measures

Intervention type: OTHER
Group type: OTHER
Intervention: TMS
Description: Measure of the cortical inhibitory capacity using TMS measures
Study: NCT02712177

Intervention type: BIOLOGICAL
Intervention: 4CMenb

Intervention type: BIOLOGICAL
Intervention: 4CMenb

Intervention type: BIOLOGICAL
Intervention: 4CMenb

Intervention type: BIOLOGICAL
Intervention: 4CMenb

Intervention type: BIOLOGICAL
Intervention: 4CMenb

Intervention type: BIOLOGICAL
Intervention: diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention type: BIOLOGICAL
Intervention: diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention type: BIOLOGICAL
Intervention: diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention type: BIOLOGICAL
Intervention: diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention type: BIOLOGICAL
Intervention: diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention type: BIOLOGICAL
Intervention: diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB
Study: NCT02432950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02186743

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Dietary Advice
Description: Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Dietary Advice
Description: Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
Study: NCT00253890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: 50 mg 1-3 capsules at bedtime for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-3 at bedtime
Study: NCT03917303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: episodic treatment with subcutaneous adalimumab for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard step-up care
Description: conventional step-up care starting with corticosteroids
Study: NCT02015520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with Clazakizumab)
Study: NCT03787966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATOPE-B
Description: Patients will perform therapeutic exercise before medical treatment and will follow the usual care after medical treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ATOPE-I
Description: Patients will follow usual care before medical treatment and will perform therapeutic exercise after medical treatment.
Study: NCT02075736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KTP laser
Study: NCT03096275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZA
Description: Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
Study: NCT03212521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Glecaprevir/pibrentasvir 100 mg/40 mg co-formulated tablets taken orally as 3 tablets once a day.
Study: NCT01356784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity
Description: Health counselling (1,5h) and graded physical activity (3×50 min/week in 10 weeks)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Pain Self-management Programme
Description: Health counselling (1,5h) and 'Chronic Pain Self-management Program' (2,5h in 6 weeks)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health counselling
Description: Health guidance (1,5h)
Study: NCT02923882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: '$100Kitchen and improved cookstove'
Study: NCT00621049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/Carboplatin/Bevacizumab/Erlotinib
Description: Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1~Docetaxel should be administered before carboplatin.~After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:~Maintenance Treatment for patients in Cohort A:~Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily~Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel/Carboplatin
Description: Adjuvant Treatment Cohort B:~Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1~Docetaxel should be administered before carboplatin.~Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment.
Study: NCT01587937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics
Description: See primary outcome for list of targeted drugs. See citations for previous publications describing the intervention.
Study: NCT02707861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibalizumab
Description: Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
Study: NCT02712177

Intervention type: BIOLOGICAL
Intervention: diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention type: BIOLOGICAL
Intervention: conjugated pneumococcal vaccine
Study: NCT01814956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipofundin N 20%
Description: Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
Study: NCT02478489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral naltrexone (PO-NTX)
Description: oral naltrexone
Study: NCT02712177

Intervention type: BIOLOGICAL
Intervention: conjugated pneumococcal vaccine
Study: NCT02075736

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TUR-P
Description: device
Study: NCT02813369

Intervention type: DRUG
Intervention: naloxegol
Description: non-interventional study where patients are exposed to naloxegol during normal clinical practice

Intervention type: DRUG
Intervention: non-PAMORA laxative
Description: non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
Study: NCT00639795

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Nerve Block
Description: One Single-injection, thoracic peripheral nerve blockade performed intraoperatively following patient induction with general endotracheal anesthesia

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Thoracic Paravertebral Nerve Block
Description: Sham single-injection thoracic peripheral nerve blockade following patient induction with general endotracheal anesthesia
Study: NCT02355275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: All patients will be provided with a Thera-Band® Loop and Band and handout describing home exercises to be performed 3 times a week for 4 weeks.
Study: NCT02531737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vargatef®
Description: Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
Study: NCT00710775

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical replacement of the aortic stenotic valve
Description: Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
Study: NCT02707861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibalizumab
Description: Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen
Description: An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen
Description: An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
Study: NCT00560430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan
Description: 80 mg per day, orally, weeks 1-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan
Description: 80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo; orally weeks 1-14
Study: NCT03262506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: The cognitive training program consists of a set of computerized exercises designed to improve the speed and accuracy of auditory information processing while engaging neuromodulatory systems involved in attention and reward. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations.
Study: NCT00683267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4975, highly purified capsaicin
Description: One dose administered by direct instillation into the surgical site

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose administered by direct instillation into the surgical site
Study: NCT04470336

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Supplement
Description: Three capsules post-breakfast Three capsules post-dinner

Intervention type: OTHER
Group type: OTHER
Intervention: Glucosamine chondroitin
Description: Three capsules post-breakfast Three capsules post-dinner

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three capsules post-breakfast Three capsules post-dinner
Study: NCT02287493

Intervention type: OTHER
Intervention: Pharmacokinetic Analysis

Intervention type: OTHER
Intervention: Pharmacokinetic Analysis
Study: NCT02253836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Description: TPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: RTV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: TAZ
Study: NCT01870245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-975
Description: Intravenous multiple dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous multiple dose
Study: NCT01578135

Intervention type: DRUG
Intervention: somatropin
Description: Patients are to fill in a questionnaire at inclusion in registry

Intervention type: DRUG
Intervention: somatropin
Description: Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
Study: NCT03648242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interruptive Clinical Decision Support
Description: An interruptive, soft-stop alert will pop up when a pediatric primary care provider open a child's electronic health record (i.e., a new window in the forefront of the screen interrupting workflow and requiring the clinician to take an action) alerting them that the child meets criteria for obesity based on their age/sex-specific BMI percentile. The pop-up alert includes:~* One-click addition of elevated BMI to problem list~* Reminder to utilize Suggested PowerPlan~* One-click access to a patient handout on evidence-based behavior change goals (screen time, sugary drinks, physical activity, sleep) and link to additional handouts and resources~* Tables displaying trends in growth measures, blood pressure and relevant laboratory tests~* Links to existing, evidence-based childhood obesity screening and management guidelines
Study: NCT02867475

Intervention type: OTHER
Group type: OTHER
Intervention: Physical activity motivation
Description: Physical activity motivation
Study: NCT04451603

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgical resection of the liver

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Y-90 radioembolization therapy is the main treatment

Intervention type: DRUG
Intervention: Drug treatment
Description: Examples include tyrosine kinase inhibitors and immune checkpoint inhibitors
Study: NCT00752713

Intervention type: PROCEDURE
Intervention: cardiac MRI
Description: cardiac MRI at one time point for group 1 after intervention for group 2 at any time point

Intervention type: PROCEDURE
Intervention: cardiac MRI
Description: cardiac MRI at one time point for group 1 after intervention for group 2 at any time point
Study: NCT05082636

Intervention type: OTHER
Intervention: Observational Study ( Tissue Biopsy )
Description: control study includes a total of 90 subjects. Of them 54 patients with early stage lung (stage I, II) cancer (Group 1) were selected from the Chest Department of Assiut University Hospital, besides 36 healthy controls; who were clinically suspicious with chest masses and proven histopathologically to be negative cancer (Group 2).obtained by fiberoptic bronchoscopy
Study: NCT00999180

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A and kinesiotherapy
Description: Stroke, Botulinum Toxin

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline and Kinesiotherapy
Description: Saline and Kinesiotherapy
Study: NCT01338987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: First Allogeneic Bone Marrow Transplant (BMT)
Description: First Allogeneic Bone Marrow Transplant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: First Allogeneic Bone Marrow Transplant (BMT)
Description: First Allogeneic Bone Marrow Transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First Allogeneic Bone Marrow Transplant (BMT)
Description: First Allogeneic Bone Marrow Transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients \<18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients \> 18 years and as a 3 month injection (adult preparation) for patients \< 18 years
Study: NCT02478489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release injectable naltrexone (XR-NTX)
Description: injectable naltrexone
Study: NCT02098135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArmeoSenso
Description: Virtual realty therapy with a touchscreen computer and movement sensors, over 42 days.
Study: NCT00696878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: Corifollitropin alfa 150 µg administered as a single subcutaneous dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSH
Description: FSH administerd subcutaneously at a dose not to exceed 225 IU/day.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: (rec)hCG
Description: (rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone administered vaginally at a dose of at least 600 mg/day.
Study: NCT01278264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.25%, 0.5 ml/kg
Description: Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.25%, 0.5 ml/kg
Description: Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet